More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

X Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 ...

Ethics Board Approval Granted for Lexaria Receives Ethics Board Approval for 12-Week Phase 1b DehydraTECH GLP-1 Study in ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global ...

DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global i ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...